Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-articular clodronate dose-ranging study in knee osteoarthritis
2018-002081-39Phase 2Terminated
- Sponsor
- Abiogen Pharma
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clodronate in knee osteoarthritis (OA) (5 arms), sponsored by Abiogen Pharma. Primary endpoint: Best change from baseline in WOMAC pain at rest in the target knee from Week 8 to Week 16. Started Jan 2019; status: terminated.
02
Drugs
clodronate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2018-002081-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002081-39.